Table 7.
Overview of most commonly reported AEs
| Carrageenan (n = 126) | Placebo (n = 128) | Total (n = 254) | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| N. of patients without AEs | 103 | 81,7% | 99 | 77,3% | 202 | 79,5% |
| Cough | 1 | 0,8% | 4 | 3,1% | 5 | 2,0% |
| Rhinitis* | 0 | 0,0% | 4 | 3,1% | 4 | 1,6% |
| Otitis media | 3 | 2,4% | 1 | 0,8% | 4 | 1,6% |
| Nasal bleeding | 3 | 2,4% | 1 | 0,8% | 4 | 1,6% |
| Fever, infection NOS** | 2 | 1,6% | 2 | 1,6% | 4 | 1,6% |
| Bronchitis | 2 | 1,6% | 2 | 1,6% | 4 | 1,6% |
| Nasal disorders NOS*** | 1 | 0,8% | 2 | 1,6% | 3 | 1,2% |
| Vomiting | 1 | 0,8% | 1 | 0,8% | 2 | 0,8% |
| Tonsillitis | 2 | 1,6% | 0 | 0,0% | 2 | 0,8% |
| Sinusitis | 0 | 0,0% | 2 | 1,6% | 2 | 0,8% |
| Rash | 0 | 0,0% | 2 | 1,6% | 2 | 0,8% |
| Nausea | 0 | 0,0% | 2 | 1,6% | 2 | 0,8% |
| Ear pain | 1 | 0,8% | 1 | 0,8% | 2 | 0,8% |
| Conjunctivitis | 1 | 0,8% | 1 | 0,8% | 2 | 0,8% |
| Adenoids | 1 | 0,8% | 1 | 0,8% | 2 | 0,8% |
| Abdominal pain | 1 | 0,8% | 1 | 0,8% | 2 | 0,8% |
*Difference between groups statistically significant, p = 0.045.
**Including pyrexia, febrile infection and viral infection (not specified).
***Including nasal itching, feeling of burning in the nose and smell disturbance.
NOS = not specified.